Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023

The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 34.45 billion in 2017 at a CAGR of 6.7%.

The objectives of this study are as follows:

• To define, describe, and forecast the vaccines market by technology, type, disease indication, route of administration, patient type, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, restraints, and industry-specific challenges)
• To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the market
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)
• To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
• To track and analyze competitive developments such as mergers and acquisitions, product developments, partnerships, agreements and collaborations, expansions, and R&D activities in the vaccines market

Research Methodology

The study estimates the vaccines market size for 2018 and projects its demand till 2023. In the primary research process, various sources from both demand side and supply side were interviewed to obtain qualitative and quantitative information for the report. Primary sources from the demand side include various industry CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from the various players in the vaccines market. For the market estimation process, both top-down and bottom-up approaches were used to estimate and validate the market size of the vaccines market as well as to estimate the market size of various other dependent submarkets. All possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data was consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report.

To know about the assumptions considered for the study, download the pdf brochure

The vaccines market is highly competitive with the presence of various players. Some of the major players operating in the market are GlaxoSmithKline, plc (UK), Pfizer, Inc. (US), Merck & Co., Inc. (US), Sanofi Pasteur SA (France), Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), MedImmune, LLC (US), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Protein Sciences Corporation (US), and Panacea Biotec (India).

Target Audience for this Report:

• Manufacturers and suppliers of vaccines
• Research and development companies
• Medical research laboratories
• Academic medical centers and universities
• Research and consulting firms
• Venture capital firms

Scope of the Report

This report categorizes the vaccines market into following segments and subsegments:

Vaccines Market, By Technology

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines

Vaccines Market, By Type

• Monovalent Vaccines
• Multivalent Vaccines

Vaccines Market, By Disease Indication

• Pneumococcal Disease
• Influenza
• DTP
• Hepatitis
• Human Papilloma Virus (HPV)
• Rotavirus
• Meningococcal Disease
• MMR (measles, mumps, and rubella)
• Varicella
• Polio
• Herpes Zoster
• Dengue
• Other Disease Indications

Vaccines Market, By Route of Administration

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Other Routes of Administration

Vaccines Market, By Patient Type

• Pediatrics
• Adults

Vaccines Market, By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia
  • Japan
  • China
  • India
  • Rest of Asia (RoA)
• Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company‘s specific needs.

The following customization options are available for this report.

Company Information

Detailed analysis and profiling of additional market players (up to 5)

Table of Contents

1 Introduction (Page No. - 18)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Market Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 22)
    2.1 Research Design
           2.1.1 Secondary Data
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Key Data From Primary Sources
                    2.1.2.2 Key Industry Insights
    2.2 Market Size Estimation
    2.3 Market Breakdown and Data Triangulation
    2.4 Market Share Estimation
    2.5 Assumptions for the Study

3 Executive Summary (Page No. - 31)

4 Premium Insights (Page No. - 35)
    4.1 Overview of the Vaccines Market
    4.2 Vaccines Market, By Type, 2018–2023
    4.3 Vaccines Market, By End User, 2018 vs 2023 (USD Billion)
    4.4 Geographic Analysis: Vaccines Market, By Technology
    4.5 Vaccines Market, By Route of Administration, 2018 vs 2023 (USD Billion)
    4.6 Geographical Snapshot of the Vaccines Market

5 Market Overview (Page No. - 39)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 High Prevalence of Infectious Diseases
                    5.2.1.2 Rising Focus on Immunization Programs
                    5.2.1.3 Growing Government Support for Vaccine Development
                    5.2.1.4 Increasing Company Initiatives to Enhance Vaccine R&D
           5.2.2 Restraints
                    5.2.2.1 High Cost of Vaccine Development
           5.2.3 Opportunities
                    5.2.3.1 High Growth Prospects in Emerging Markets
                    5.2.3.2 Focus on Therapeutic Vaccines
                    5.2.3.3 Use of Adjuvants in Vaccines
           5.2.4 Challenges
                    5.2.4.1 Inadequate Access to Vaccines
                    5.2.4.2 Product Recalls

6 Industry Insights (Page No. - 46)
    6.1 Regulatory Landscape
           6.1.1 North America
           6.1.2 Europe
           6.1.3 Asia
           6.1.4 RoW
    6.2 Key Pipeline Products
    6.3 New Vaccine Opportunities
           6.3.1 Hiv
                    6.3.1.1 HIV Vaccine: Product Pipeline
                    6.3.1.2 HIV Vaccine: Public-Private Initiatives
                    6.3.1.3 HIV Vaccine: Funding
           6.3.2 Malaria
                    6.3.2.1 Malaria Vaccine: Product Pipeline
                    6.3.2.2 Malaria Vaccine: Public-Private Initiatives
           6.3.3 Zika
                    6.3.3.1 Zika Vaccine: Product Pipeline
                    6.3.3.2 Zika Vaccine: Public-Private Initiatives
                    6.3.3.3 Zika Vaccine: Funding
           6.3.4 Ebola
                    6.3.4.1 Ebola Vaccine: Product Pipeline
                    6.3.4.2 Ebola Vaccine: Public-Private Initiatives
                    6.3.4.3 Ebola Vaccine: Funding

7 Vaccines Market, By Technology (Page No. - 57)
    7.1 Introduction
    7.2 Conjugate Vaccines
    7.3 Inactivated and Subunit Vaccines
    7.4 Live Attenuated Vaccines
    7.5 Recombinant Vaccines
    7.6 Toxoid Vaccines

8 Vaccines Market, By Type (Page No. - 65)
    8.1 Introduction
    8.2 Monovalent Vaccines
    8.3 Multivalent Vaccines

9 Vaccines Market, By Disease Indication (Page No. - 70)
    9.1 Introduction
    9.2 Pneumococcal Disease
    9.3 DTP
    9.4 Influenza
    9.5 HPV
    9.6 Meningococcal Disease
    9.7 Polio
    9.8 Rotavirus
    9.9 Hepatitis
    9.10 MMR
    9.11 Varicella
    9.12 Dengue
    9.13 Herpes Zoster
    9.14 Other Disease Indications

10 Vaccines Market, By Route of Administration (Page No. - 87)
     10.1 Introduction
     10.2 Intramuscular and Subcutaneous Administration
     10.3 Oral Administration
     10.4 Other Routes of Administration

11 Vaccines Market, By Patient Type (Page No. - 92)
     11.1 Introduction
     11.2 Pediatric Patients
     11.3 Adult Patients

12 Vaccines Market, By Region (Page No. - 97)
     12.1 Introduction
     12.2 North America
             12.2.1 US
             12.2.2 Canada
     12.3 Europe
             12.3.1 Germany
             12.3.2 UK
             12.3.3 France
             12.3.4 Italy
             12.3.5 Spain
             12.3.6 RoE
     12.4 Asia
             12.4.1 Japan
             12.4.2 China
             12.4.3 India
             12.4.4 Rest of Asia (Roa)
     12.5 Rest of the World (RoW)

13 Competitive Landscape (Page No. - 127)
     13.1 Overview
     13.2 Market Share Analysis
     13.3 Competitive Situation and Trends
             13.3.1 Agreements, Partnerships, and Collaborations
             13.3.2 Product Launches and Approvals
             13.3.3 Acquisitions
             13.3.4 Expansions

14 Company Profiles (Page No. - 133)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     14.1 Pfizer
     14.2 Glaxosmithkline
     14.3 Merck
     14.4 Sanofi Pasteur
     14.5 CSL Limited
     14.6 Emergent Biosolutions
     14.7 Johnson & Johnson
     14.8 Medimmune, LLC (A Subsidiary of Astrazeneca)
     14.9 Astellas Pharma
     14.10 Serum Institute of India
     14.11 Bavarian Nordic
     14.12 Mitsubishi Tanabe Pharma Corporation
     14.13 Daiichi Sankyo Company
     14.14 Panacea Biotec
     14.15 Biological E

*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.

15 Appendix (Page No. - 178)
     15.1 Discussion Guide
     15.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     15.3 Available Customizations
     15.4 Related Reports
     15.5 Author Details

List of Tables (93 Tables)

Table 1 Incidence of Diseases
Table 2 NIH Funding for Vaccine Research, 2013–2018 (USD Million)
Table 3 Immunization Coverage, By Disease, 2015 vs 2016
Table 4 Regulatory Authorities in Europe
Table 5 Regulatory Authorities in Asia
Table 6 Key Pipeline Vaccines
Table 7 Estimated Investments in HIV Vaccines, By Investor (2015–2016)
Table 8 Ebola Projects Funded By Ec (2014–2020)
Table 9 Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 10 Cost of Meningococcal Conjugate Vaccines
Table 11 Conjugate Vaccines Market, By Region, 2016–2023 (USD Million)
Table 12 Examples of Inactivated and Subunit Vaccines
Table 13 Inactivated and Subunit Vaccines Market, By Region, 2016–2023 (USD Million)
Table 14 Live Attenuated Vaccines Market, By Region, 2016–2023 (USD Million)
Table 15 Examples of Recombinant Vaccines
Table 16 Recombinant Vaccines Market, By Region, 2016–2023 (USD Million)
Table 17 Toxoid Vaccines Market, By Region, 2016–2023 (USD Million)
Table 18 Vaccines Market, By Type, 2016–2023 (USD Million)
Table 19 Monovalent Vaccines Market, By Region, 2016–2023 (USD Million)
Table 20 Examples of Notable Multivalent Vaccines Available in the Market
Table 21 Multivalent Vaccines Market, By Region, 2016–2023 (USD Million)
Table 22 Vaccines Market, By Disease Indication, 2016–2023 (USD Million)
Table 23 List of Commercially Available Pneumococcal Vaccines in the Market
Table 24 Vaccines Market for Pneumococcal Disease, By Region, 2016–2023 (USD Million)
Table 25 List of Commercially Available DTP Vaccines in the Market
Table 26 Vaccines Market for DTP, By Region, 2016–2023 (USD Million)
Table 27 List of Commercially Available Influenza Vaccines in the Market
Table 28 Vaccines Market for Influenza, By Region, 2016–2023 (USD Million)
Table 29 List of Commercially Available HPV Vaccines in the Market
Table 30 Vaccines Market for HPV, By Region, 2016–2023 (USD Million)
Table 31 List of Commercially Available HPV Vaccines in the Market
Table 32 Vaccines Market for Meningococcal Disease, By Region, 2016–2023 (USD Million)
Table 33 List of Commercially Available Polio Vaccines in the Market
Table 34 Vaccines Market for Polio, By Region, 2016–2023 (USD Million)
Table 35 List of Commercially Available Rotavirus Vaccines in the Market
Table 36 Vaccines Market for Rotavirus, By Region, 2016–2023 (USD Million)
Table 37 List of Commercially Available Hepatitis Vaccines in the Market
Table 38 Vaccines Market for Hepatitis, By Region, 2016–2023 (USD Million)
Table 39 List of Commercially Available MMR Vaccines in the Market
Table 40 Vaccines Market for MMR, By Region, 2016–2023 (USD Million)
Table 41 List of Commercially Available Varicella Vaccines in the Market
Table 42 Vaccines Market for Varicella, By Region, 2016–2023 (USD Million)
Table 43 Vaccines Market for Herpes Zoster, By Region, 2016–2023 (USD Million)
Table 44 List of Commercially Available Vaccines for Other Disease Indications in the Market
Table 45 Vaccines Market for Other Disease Indications, By Region, 2016–2023 (USD Million)
Table 46 Vaccines Market, By Route of Administration, 2016–2023 (USD Million)
Table 47 Vaccines Market for Intramuscular and Subcutaneous Administration, By Region, 2016–2023 (USD Million)
Table 48 Vaccines Market for Oral Administration, By Region, 2016–2023 (USD Million)
Table 49 Vaccines Market for Other Routes of Administration, By Region, 2016–2023 (USD Million)
Table 50 Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 51 Vaccines Market for Pediatric Patients, By Region, 2016–2023 (USD Million)
Table 52 North America: Vaccines Market for Pediatric Patients, By Country, 2016–2023 (USD Million)
Table 53 Vaccines Market for Adult Patients, By Region, 2016–2023 (USD Million)
Table 54 North America: Vaccines Market for Adult Patients, By Country, 2016–2023 (USD Million)
Table 55 Vaccines Market, By Region, 2016–2023 (USD Million)
Table 56 North America: Vaccines Market, By Country, 2016–2023 (USD Million)
Table 57 North America: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 58 North America: Vaccines Market, By Type, 2016–2023 (USD Million)
Table 59 North America: Vaccines Market, 2016–2023 (USD Million)
Table 60 North America: Vaccines Market, 2016–2023 (USD Million)
Table 61 North America: Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 62 US: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 63 US: Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 64 Canada: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 65 Canada: Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 66 Europe: Vaccines Market, By Country, 2016–2023 (USD Million)
Table 67 Europe: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 68 Europe: Vaccines Market, By Type, 2016–2023 (USD Million)
Table 69 Europe: Vaccines Market, By Disease Indication, 2016–2023 (USD Million)
Table 70 Europe: Vaccines Market, By Route of Administration, 2016–2023 (USD Million)
Table 71 Europe: Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 72 Germany: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 73 UK: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 74 France: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 75 Italy: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 76 Spain: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 77 RoE: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 78 Asia: Health Expenditure Per Capita, By Country, 2000, 2014 & 2016 (USD)
Table 79 Asia: Vaccines Market, By Country, 2016–2023 (USD Million)
Table 80 Asia: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 81 Asia: Vaccines Market, By Type, 2016–2023 (USD Million)
Table 82 Asia: Vaccines Market, By Disease Indication, 2016–2023 (USD Million)
Table 83 Asia: Vaccines Market, By Route of Administration, 2016–2023 (USD Million)
Table 84 Asia: Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 85 Japan: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 86 China: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 87 India: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 88 RoA: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 89 RoW: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 90 RoW: Vaccines Market, By Type, 2016–2023 (USD Million)
Table 91 RoW: Vaccines Market, 2016–2023 (USD Million)
Table 92 RoW: Vaccines Market, 2016–2023 (USD Million)
Table 93 RoW: Vaccines Market, By Patient Type, 2016–2023 (USD Million)

List of Figures (46 Figures)

Figure 1 Vaccines Market Segmentation
Figure 2 Market Size Estimation: Bottom-Up Approach
Figure 3 Market Size Estimation: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 Vaccines Market, By Technology, 2018–2023
Figure 7 Vaccines Market, By Type, 2018 vs 2023 (USD Billion)
Figure 8 Vaccines Market, By Disease Indication, 2018 vs 2023 (USD Billion)
Figure 9 Vaccines Market, By Route of Administration, 2018 vs 2023 (USD Billion)
Figure 10 Vaccines Market, By Patient Type, 2018 vs 2023 (USD Billion)
Figure 11 Geographical Snapshot of the Vaccines Market
Figure 12 High Prevalence of Diseases and Rising Focus on Immunization Programs are Driving Market Growth
Figure 13 Monovalent Vaccines Segment to Register the Highest Growth During the Forecast Period
Figure 14 Pediatrics Segment to Dominate the Vaccines Market in 2023 (USD Billion)
Figure 15 Conjugate Vaccines Segment to Hold Largest Share of the Vaccines Market in 2018
Figure 16 Intramuscular and Subcutaneous Administration Segment to Register the Highest Growth During the Forecast Period
Figure 17 US to Dominate the Vaccines Market in 2018
Figure 18 Vaccine Market: Drivers, Restraints, Opportunities, and Challenges
Figure 19 Regulatory Approval Process for Vaccines
Figure 20 R&D Funding for HIV Preventive Vaccines, By Investor, 2016
Figure 21 Conjugate Vaccines Segment to Dominate the Vaccines Market During the Forecast Period
Figure 22 Monovalent Vaccines to Grow at the Highest Rate in the Vaccines Market, By Type
Figure 23 Pneumococcal Disease Segment to Lead Vaccines Market, By Disease Indication, During 2018–2023
Figure 24 Vaccines Market for Dengue, 2016–2023 (USD Million)
Figure 25 Intramuscular and Subcutaneous Administration Segment to Account for the Vaccines Market, 2018–2023 (USD Million)
Figure 26 Pediatric Patients Segment to Account for the Largest Share of the Vaccines Market, 2018 (USD Million)
Figure 27 North America: Vaccines Market Snapshot
Figure 28 Europe: Vaccines Market Snapshot
Figure 29 Asia: Vaccines Market Snapshot
Figure 30 RoW: Vaccines Market Snapshot
Figure 31 Key Developments in the Vaccine Market From 2015 to 2018
Figure 32 Market Evolution Framework
Figure 33 Vaccines Market Share Analysis, By Key Player, 2017
Figure 34 Pfizer: Company Snapshot (2017)
Figure 35 Glaxosmithkline: Company Snapshot (2017)
Figure 36 Merck: Company Snapshot (2017)
Figure 37 Sanofi Pasteur: Company Snapshot (2017)
Figure 38 CSL Limited: Company Snapshot (2017)
Figure 39 Emergent Biosolutions: Company Snapshot (2017)
Figure 40 Johnson & Johnson: Company Snapshot (2017)
Figure 41 Astrazeneca: Company Snapshot (2017)
Figure 42 Astellas Pharma: Company Snapshot (2017)
Figure 43 Bavarian Nordic: Company Snapshot (2017)
Figure 44 Mitsubishi Tanabe Pharma Corporation: Company Snapshot (2017)
Figure 45 Daiichi Sankyo Company: Company Snapshot (2017)
Figure 46 Panacea Biotec: Company Snapshot (2017)

The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. Factors such as rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing company initiatives to enhance R&D are driving the vaccines market.

This report segments the vaccines market into technology, type, disease indication, route of administration, patient type, and region. Based on technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate vaccines segment is expected to account for the largest share of the vaccines market, in 2018. Rising prevalence of diseases and increasing government initiatives are the key factors driving the growth of this segment.

Based on the type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent vaccines segment is projected to register the highest CAGR during the forecast period. Rising prevalence of diseases and increasing government and nongovernment initiatives to promote immunization are the key factors driving the growth of this segment.

Based on disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, dengue, and other disease indications. The meningococcal disease segment is expected to witness the highest growth during the forecast period. The growth of this segment is primarily attributed to high incidence of meningococcal disease and increasing government investments in meningococcal vaccination programs.

Based on route of administration, the vaccines market is segmented into intramuscular and subcutaneous administration, oral administration, and other routes of administration. The intramuscular and subcutaneous administration segment is expected to hold the largest share of the vaccines market, in 2018. The growth of this segment is attributed to benefits associated with this mode of administration such as faster absorption of medication in blood, and lower rate of injection site reactions.

Based on the patient type, the vaccines market is segmented into pediatrics and adults. The adult segment is expected to register the highest CAGR during the forecast period. Factors like the increasing investments by companies for the development of new adult vaccines and government initiatives for immunization are driving the growth of this segment.

In 2018, North America is expected to dominate the market, followed by Europe. The high growth of the North American market is attributed to the factors such as increasing investments by government organizations and companies to promote immunization as well as develop new vaccines.

While North America is expected to dominate the market in 2018, Asia is expected to register the highest CAGR during the forecast period. The high growth in this market is attributed to increasing investments by companies in the emerging economies such as India and China and rising disposable income.

While the vaccines market presents significant growth opportunities, market growth may be hindered due to the high cost of vaccine development. The vaccines market is highly competitive with several big and small players. Prominent players in the vaccines market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), GlaxoSmithKline, plc (UK), Johnson & Johnson (US), MedImmune, LLC (US), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi Pasteur SA (France), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Biological E (India), and Panacea Biotec (India).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst